Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK ...

Djokovic’s inspired victory over Carlos Alcaraz in Paris last August, two months after the Spanish sensation won the French ...

Brenna Ducatte accounted for over half of her team’s points Wednesday night in Saranac’s 42-19 win over Northern Adirondack ...

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

Saturday was a rivalry game and an early CVAC contest for Beekmantown and Plattsburgh. But, the night was bigger than just a ...

Investors are weighing Nvidia's big AI plans and puzzling over Trump's tariff policy in the wait for fresh jobs data.

Shares of Moderna (MRNA), one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, were up nearly 10% in early trading ...